Product category:
Calibration and Laboratory Instruments
News Release from: LGC | Subject: Genetic diagnostic
Edited by the Manufacturingtalk Editorial
Team on 15 June 2005
Screening service with analytical
service
LGC a laboratory providing advanced chemical, biochemical and forensic analysis will be launching its new screening service of the genes associated with non-polyposis colorectal cancer
LGC, Europe's leading independent analytical laboratory providing advanced chemical, biochemical and forensic analysis will be launching its new screening service of the genes associated with non-polyposis colorectal cancer (HNPCC) with a stand at the First Conference of InSiGHT (International Society for Gastrointestinal Hereditary Tumours), at the Hilton Newcastle Gateshead, 14 - 17 June 2005 LGC is also the primary sponsor of the UK CGG (Cancer Genetics Group) meeting, a satellite meeting which will run alongside the conference on 14 June
This article was originally published on Manufacturingtalk on 10 Mar 2003 at 8.00am (UK)
Related stories
LGC Launches ADME-Tox Screening Service
Bioanalytical services at LGC's new ADME-Tox laboratory include in vitro drug metabolism, cellular toxicology and prediction of gastrointestinal transport.
Phytochemical Reference Standards Now Available
Over 2500 high purity ChromaDex phytochemical - or herbal - reference standards are now available exclusively from LGC Promochem throughout Europe.
The new service, which will be offered to European as well as NHS customers, is the screening of the DNA mismatch repair genes hMLH1, hMSH2 and hMSH6 for variations that may be associated with HNPCC.
Developed and validated in a series of blind trials with collaborator groups within and outside the NHS, including three separate colon cancer centres and the Life Knowledge Park in Newcastle, LGC's colon cancer screening service provides the assignation and reporting of exact mutations and positions and detection of single nucleotide variants.
It is an ISO 17025 and IVDD compliant service and promises rapid turnaround times to meet the individual referrer's requirements.
Dr Paul Debenham, Director of Life Sciences at LGC, said: "The detection of inherited mutations in certain key genes linked to cancers can provide both diagnostic information about the disease in specific patients, and also enable predictive screening of family members.
Using mass spectrometry combined with LGC's proprietary analysis software, we are now able to rapidly detect exact changes in the DNA of a given patient, and simultaneously characterise the gene mutation with base change and position assigned in one single step." He added:"We are also able to analyse considerable additional DNA sequences adjacent to the actual coding DNA so as to provide a more comprehensive sweep of the gene information.
We are therefore delighted to be at the First Conference of InSiGHT to launch this reliable, rapid and cost-effective gene sequence screening service." In addition to launching the service, LGC's Life Sciences R and D Manager, Jim Thomson, will give a presentation on 'Mutation Detection using MALDI-ToF Mass Spectrometry - A Validated Science', at the UK CGG (Cancer Genetics Group) satellite meeting at the Centre for Life at 13.35pm, 14 June.
• LGC: contact details and other news
• Email this article to a colleague
• Register for the free Manufacturingtalk email newsletter
• Manufacturingtalk Home Page
Search the Pro-Talk network of sites
